InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,457.28
(
-0.25%
)
US TECH 100
18,231.80
(
0.29%
)
Dow Jones
40,533.09
(
-0.73%
)
Brent Oil
68.82
(
-4.04%
)
Bitcoin
56,715.17
(
-0.54%
)
Post# of 253076
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: biomaven0 post# 134284

Wednesday, 01/04/2012 12:16:25 AM

Wednesday, January 04, 2012 12:16:25 AM

Post# of 253076

Nexavar sales are currently around $1B/yr, although I'm not sure of the split between RCC and HCC and other indications. So a drug that is superior to Nexavar and has a similar S/E profile is likely to be at least a reasonable commercial success.

The expectation is that tivo's S/E profile is better than Nexavar, isn't it?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up